nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2012 | Original Article

Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with ¹⁸F-ML-10

verfasst von: Aaron M. Allen, Miri Ben-Ami, Ayelet Reshef, Adam Steinmetz, Yulia Kundel, Edna Inbar, Ruth Djaldetti, Tal Davidson, Eyal Fenig, Ilan Ziv

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Early assessment of tumor response to therapy is vital for treatment optimization for the individual cancer patient. Induction of apoptosis is an early and nearly universal effect of anticancer therapies. The purpose of this study was to assess the performance of ¹⁸F-ML-10, a novel PET radiotracer for apoptosis, as a tool for the early detection of response of brain metastases to whole-brain radiation therapy (WBRT).

Materials and methods

Ten patients with brain metastases treated with WBRT at 30 Gy in ten daily fractions were enrolled in this trial. Each patient underwent two ¹⁸F-ML-10 PET scans, one prior to the radiation therapy (baseline scan), and the second after nine or ten fractions of radiotherapy (follow-up scan). MRI was performed at 6–8 weeks following completion of the radiation therapy. Early treatment-induced changes in tumor ¹⁸F-ML-10 uptake on the PET scan were measured by voxel-based analysis, and were then evaluated by correlation analysis as predictors of the extent of later changes in tumor anatomical dimensions as seen on MRI scans 6–8 weeks after completion of therapy.

Results

In all ten patients, all brain lesions were detected by both MRI and the ¹⁸F-ML-10 PET scan. A highly significant correlation was found between early changes on the ¹⁸F-ML-10 scan and later changes in tumor anatomical dimensions (r = 0.9).

Conclusion

These results support the potential of ¹⁸F-ML-10 PET as a novel tool for the early detection of response of brain metastases to WBRT.

Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol. 2005;4(5):289–98.PubMedCrossRef

Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai SK, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys. 2008;72(5):1311–8.PubMedCrossRef

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.PubMedCrossRef

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91.PubMedCrossRef

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.PubMedCrossRef

Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):71–83.PubMedCrossRef

Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63(1):37–46.PubMedCrossRef

Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol. 2007;25(10):1260–6.PubMedCrossRef

Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007;10(1-2):13–29.PubMedCrossRef

10.

Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 2008;9(10):1002–11.PubMedCrossRef

11.

Meiler J, Schuler M. Therapeutic targeting of apoptotic pathways in cancer. Curr Drug Targets. 2006;7(10):1361–9.PubMedCrossRef

12.

Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4(12):721–9.PubMedCrossRef

13.

Fernandez-Luna JL. Apoptosis regulators as targets for cancer therapy. Clin Transl Oncol. 2007;9(9):555–62.PubMedCrossRef

14.

Meyn RE, Milas L, Ang KK. The role of apoptosis in radiation oncology. Int J Radiat Biol. 2009;85(2):107–15.PubMedCrossRef

15.

Cohen A, Shirvan A, Levin G, Grimberg H, Reshef A, Ziv I. From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res. 2009;19(5):625–37.PubMedCrossRef

16.

Hoglund J, Shirvan A, Antoni G, Gustavsson SA, Langstrom B, Ringheim A, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med. 2011;52(5):720–5.PubMedCrossRef

17.

Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, Cohen A, et al. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med. 2008;49(9):1520–8.PubMedCrossRef

18.

Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med. 2010;51(6):837–40.PubMedCrossRef

19.

Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res. 2011;17(14):4751–60.PubMedCrossRef

20.

Kwee TC, Galban CJ, Tsien C, Junck L, Sundgren PC, Ivancevic MK, et al. Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas. J Magn Reson Imaging. 2010;31(3):531–7.PubMedCrossRef

21.

Ma B, Meyer CR, Pickles MD, Chenevert TL, Bland PH, Galban CJ, et al. Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging. 2009;21:276–87.PubMedCrossRef

22.

Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102(15):5524–9.

23.

Aloya R, Shirvan A, Grimberg H, Reshef A, Levin G, Kidron D, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis. 2006;11(12):2089–101.PubMedCrossRef

24.

Hoebers FJ, Kartachova M, de Bois J, van den Brekel MW, van Tinteren H, van Herk M, et al. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2008;35(3):509–18.PubMedCrossRef

25.

Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med. 2005;46(4):658–66.PubMed

26.

Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A. 2009;106(38):16375–80.PubMedCrossRef

27.

Zhou D, Chu W, Chen DL, Wang Q, Reichert DE, Rothfuss J, et al. [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. Org Biomol Chem. 2009;7(7):1337–48.PubMedCrossRef

28.

Ariji Y, Fuwa N, Kodaira T, Tachibana H, Nakamura T, Satoh Y, et al. False-positive positron emission tomography appearance with 18F-fluorodeoxyglucose after definitive radiotherapy for cancer of the mobile tongue. Br J Radiol. 2009;82(973):e3–7.PubMedCrossRef

29.

Hentschel M, Appold S, Schreiber A, Abolmaali N, Abramyuk A, Dorr W, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2011;38(7):1203–11.PubMedCrossRef

Titel: Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10
verfasst von: Aaron M. Allen
Miri Ben-Ami
Ayelet Reshef
Adam Steinmetz
Yulia Kundel
Edna Inbar
Ruth Djaldetti
Tal Davidson
Eyal Fenig
Ilan Ziv
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2150-8

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with ¹⁸F-ML-10

Abstract

Purpose

Materials and methods

Results

Conclusion

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

The motivations and methodology for high-throughput PET imaging of small animals in cancer research

P. Shreve and D. W. Townsend (Eds): Clinical PET-CT in Radiology: Integrated Imaging in Oncology

Can animal data predict human outcome? Problems and pitfalls of translational animal research

Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection

Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F]ICF01006, a highly promising melanoma PET tracer

Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies: reply to Ballinger